WCLC 2024 | Dr. Kenneth O’Byrne：Spatial Metabolic Mapping Accelerates Biomarker Development for Predicting ICI Therapy Responses

WCLC 2024 | Dr. Kenneth O’Byrne：Spatial Metabolic Mapping Accelerates Biomarker Development for Predicting ICI Therapy Responses

Immune checkpoint inhibitors (ICIs) have brought new hope to the treatment of non-small cell lung cancer (NSCLC). However, their effectiveness is limited to only a subset of patients. Current biomarkers, such as tumor mutational burden (TMB) and PD-L1, show limited predictive power. According to Dr. Kenneth O’Byrne’s report(Icon Cancer Centre Greenslope) at the 2024 World Conference on Lung Cancer (WCLC), tests revealing high TMB or PD-L1 positivity only have a positive predictive value of around 40%.
Dr. Meiqi Shi’s In-Depth Discussion: Key Topics in Lung Cancer Immunotherapy | CSCO Lung Cancer Standardized Treatment Workshop

Dr. Meiqi Shi’s In-Depth Discussion: Key Topics in Lung Cancer Immunotherapy | CSCO Lung Cancer Standardized Treatment Workshop

Since the FDA approval of the first lung cancer immunotherapy regimen in 2015 based on the CheckMate-017 and 057 studies, lung cancer immunotherapy has evolved significantly over the past decade, becoming the first-line standard of care for patients with driver mutation-negative non-small cell lung cancer (NSCLC). However, as evidence accumulates and clinical experience grows, some issues continue to stir debate. During the recent "2024 CSCO Lung Cancer Standardized Treatment Workshop," Oncology Frontier interviewed Dr. Meiqi Shi from Jiangsu Cancer Hospital to discuss key topics such as the choice of immunotherapy, treatment for brain metastases, immunotherapy rechallenge, and management of adverse events.
ESMO 2024 | Dr. Tian Yang on New Liver Cancer Screening Method using Digital PCR Detection of Circulating Tumor DNA Methylation Markers

ESMO 2024 | Dr. Tian Yang on New Liver Cancer Screening Method using Digital PCR Detection of Circulating Tumor DNA Methylation Markers

Liver cancer, often referred to as the “silent killer,” is frequently diagnosed at an advanced stage. Current screening methods such as alpha-fetoprotein (AFP) testing and ultrasound lack sufficient sensitivity and specificity. Therefore, there is an urgent need for more efficient, accurate, and cost-effective screening tools. At the 2024 ESMO conference, former President of the Korean Surgical Society and Professor at Inje University Haeundae Paik Hospital, Wang Hee-Jung, presented a novel method based on digital PCR detection of circulating tumor DNA methylation markers, demonstrating promising sensitivity and specificity results. Oncology Frontier invited Dr. Tian Yang from the Third Affiliated Hospital of Naval Medical University to provide insights on this study.
Dr. Arnaud Pigneux: Sharing the Innovative Achievements of AML Treatment by the French Innovative Leukemia Organization (FILO)

Dr. Arnaud Pigneux: Sharing the Innovative Achievements of AML Treatment by the French Innovative Leukemia Organization (FILO)

Recently, the 11th Sino-French Hematology Academic Conference successfully took place in Tianjin, China, attracting hundreds of top authorities and scholars in the field of hematology from both domestic and international circles. During the conference, "Hematology Frontier" specially invited Dr. Arnaud Pigneux from Haut-Leveque Hospital, University of Bordeaux, to discuss the innovative practice achievements of the French Innovative Leukemia Organization (FILO).
Exclusive Interview with Dr. Xiaobing Chen: New Strategies for Early Screening and Immunotherapy in Esophageal Cancer

Exclusive Interview with Dr. Xiaobing Chen: New Strategies for Early Screening and Immunotherapy in Esophageal Cancer

At the 2024 Chinese Anti-Cancer Association (CACA) Integration of Esophageal Cancer Academic Conference, Oncology Frontier invited Dr. Xiaobing Chen, Secondary Professor/Chief Physician at the Department of Internal Medicine at Henan Cancer Hospital and Chair of the CACA Esophageal Tumor Integrated Rehabilitation Committee, to provide an in-depth analysis of early signs of esophageal cancer, screening methods, and innovative strategies for clinical application of immune checkpoint inhibitors.
Dr. Frédéric Millot: Future Directions in the Treatment of Chronic Myeloid Leukemia (CML) in Children

Dr. Frédéric Millot: Future Directions in the Treatment of Chronic Myeloid Leukemia (CML) in Children

Recently, the 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, was successfully held in Tianjin, attracting hundreds of top experts and scholars in the field of hematology from China and abroad. During the conference, Dr. Frédéric Millot from the University Hospital of Poitiers, France, was invited by "Hematology Frontier" to share the future directions in the treatment of chronic myeloid leukemia (CML) in children.
Dr. Lihua Qiu and Dr. Swaminathan Iyer Discuss the Latest Advances and Optimal Strategies for Peripheral T-Cell Lymphoma Treatment

Dr. Lihua Qiu and Dr. Swaminathan Iyer Discuss the Latest Advances and Optimal Strategies for Peripheral T-Cell Lymphoma Treatment

The 5th Tianjin International Lymphoma Academic Conference, serving as an academic platform to foster international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and collaboration in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Dr. Lihua Qiu from Tianjin Medical University Cancer Institute and Hospital and Dr. Swaminathan Iyer from The University of Texas MD Anderson Cancer Center to engage in a China-International dialogue, reviewing the latest therapeutic advances in peripheral T-cell lymphoma (PTCL) and the optimization direction of treatment strategies.
STTT | Breakthrough in Kidney Cancer by Academician Xu Zhang’s Team! Neoadjuvant Regimen of Toripalimab Combined with Axitinib Assists RCC Patients with Tumor Thrombus Downstaging

STTT | Breakthrough in Kidney Cancer by Academician Xu Zhang’s Team! Neoadjuvant Regimen of Toripalimab Combined with Axitinib Assists RCC Patients with Tumor Thrombus Downstaging

Radical nephrectomy combined with venous tumor thrombus resection is the preferred treatment for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) and can significantly improve patient prognosis. Preoperative neoadjuvant therapy aimed at reducing tumor thrombus level and grade is of great importance in reducing perioperative risks. Recently, the NEOTAX study, led by Academician Xu Zhang, Professor Xin Ma, and Professor Liangyou Gu from the Chinese People's Liberation Army General Hospital, was presented at the ESMO Congress (1701P). The study demonstrated that the neoadjuvant regimen of toripalimab combined with axitinib reduced tumor thrombus levels in 96.0% of RCC patients with IVC-TT and achieved thrombus downstaging in 44% of patients, thereby simplifying the surgical process. The study results were published in the Nature sub-journal Signal Transduction and Targeted Therapy (IF: 40.8). The combined treatment showed significant efficacy in reducing IVC-TT and improving surgical feasibility, offering a new direction for improving the prognosis of such patients. Below are the study details.